Should I buy or sell Alpha Tau Medical stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRTS shares. View DRTS analyst ratings or view top-rated stocks .

What is Alpha Tau Medical's stock price target for 2024?

3 equities research analysts have issued 1 year price targets for Alpha Tau Medical's shares. Their DRTS share price targets range from $8.00 to $23.00. On average, they anticipate the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts .

How have DRTS shares performed in 2023?

Alpha Tau Medical's stock was trading at $3.18 on January 1st, 2023. Since then, DRTS shares have increased by 0.6% and is now trading at $3.20. View the best growth stocks for 2023 here .

Are investors shorting Alpha Tau Medical?

Alpha Tau Medical saw a decrease in short interest in November. As of November 15th, there was short interest totaling 65,100 shares, a decrease of 8.2% from the October 31st total of 70,900 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is presently 2.5 days. Currently, 0.2% of the shares of the company are short sold. View Alpha Tau Medical's Short Interest .

When is Alpha Tau Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our DRTS earnings forecast .

How were Alpha Tau Medical's earnings last quarter?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) issued its quarterly earnings results on Thursday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05.

Who are Alpha Tau Medical's major shareholders?

Alpha Tau Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hoylecohen LLC (0.39%), Levin Capital Strategies L.P. (0.12%) and Citigroup Inc. (0.02%).

How do I buy shares of Alpha Tau Medical?

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Alpha Tau Medical Stock Price, News & Analysis (NASDAQ:DRTS)

$3.20

-0.01 (-0.31%)

(As of 05:28 PM ET)

Compare

Today's Range: $3.08
▼
$3.33
50-Day Range: $2.79
▼
$3.89
52-Week Range: $2.75
▼
$5.95

Volume: 42,863 shs
Average Volume: 55,661 shs
Market Capitalization: $221.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.33

Alpha Tau Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 316.7% Upside
$13.33 Price Target
Short Interest: Healthy
0.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.46) to ($0.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

438th out of 949 stocks

Surgical & Medical Instruments Industry

57th out of 95 stocks

3.5

Analyst's Opinion

Consensus Rating
Alpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.33, Alpha Tau Medical has a forecasted upside of 316.7% from its current price of $3.20.
Amount of Analyst Coverage
Alpha Tau Medical has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.17% of the float of Alpha Tau Medical has been sold short.
Short Interest Ratio / Days to Cover
Alpha Tau Medical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alpha Tau Medical has recently decreased by 8.18%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alpha Tau Medical does not currently pay a dividend.
Dividend Growth
Alpha Tau Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DRTS.

2.8

News and Social Media Coverage

News Sentiment
Alpha Tau Medical has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Alpha Tau Medical this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.47% of the stock of Alpha Tau Medical is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.46) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alpha Tau Medical is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alpha Tau Medical is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alpha Tau Medical has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alpha Tau Medical Stock (NASDAQ:DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

DRTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRTS Stock News Headlines

November 28, 2023 | finance.yahoo.com

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

November 26, 2023 | americanbankingnews.com

Analyzing Intelligent Bio Solutions (NASDAQ:INBS) & Alpha Tau Medical (NASDAQ:DRTS)

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 24, 2023 | americanbankingnews.com

HC Wainwright Research Analysts Lift Earnings Estimates for Alpha Tau Medical Ltd. (NASDAQ:DRTS)

November 21, 2023 | americanbankingnews.com

Alpha Tau Medical's (DRTS) "Buy" Rating Reaffirmed at HC Wainwright

November 20, 2023 | finance.yahoo.com

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

November 19, 2023 | americanbankingnews.com

Alpha Tau Medical (NASDAQ:DRTS) Price Target Cut to $8.00

November 17, 2023 | markets.businessinsider.com

Analyst Ratings for Alpha Tau Medical

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 16, 2023 | msn.com

Alpha Tau Medical GAAP EPS of $0.31

October 30, 2023 | finance.yahoo.com

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

September 16, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn Situation

September 14, 2023 | stockhouse.com

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

August 24, 2023 | finance.yahoo.com

Alpha Tau Medical to Participate in September Investor Conferences

August 17, 2023 | finance.yahoo.com

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

August 2, 2023 | finance.yahoo.com

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

May 25, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)

May 24, 2023 | finance.yahoo.com

Alpha Tau Medical to Participate in June Investor Conferences

May 23, 2023 | msn.com

Recap: Alpha Tau Medical Q1 Earnings

May 22, 2023 | finance.yahoo.com

Should You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?

May 18, 2023 | markets.businessinsider.com

Alpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. Wainwright

May 17, 2023 | finance.yahoo.com

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 11, 2023 | finance.yahoo.com

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

May 3, 2023 | finance.yahoo.com

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

April 24, 2023 | msn.com

Alpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapy

March 8, 2023 | finance.yahoo.com

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

March 1, 2023 | finance.yahoo.com

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

See More Headlines

Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/16/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DRTS
CUSIP: N/A
CIK: 1871321
Web: healthcarecapitalcorp.com
Phone: 972-3577-4115
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.33
High Stock Price Target: $23.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +315.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.02%
Return on Assets: -22.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.66
Quick Ratio: 18.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 2.47

Miscellaneous

Outstanding Shares: 69,370,000
Free Float: 41,971,000
Market Cap: $222.68 million
Optionable: Not Optionable
Beta: 0.93

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Uzi Sofer (Age 53)
CEO & Chairman
Comp: $1.58M
Mr. Raphi Levy (Age 38)
Chief Financial Officer
Comp: $1.24M
Mr. Amnon Gat (Age 48)
Chief Operations Officer
Comp: $497k
Mr. Ronen Segal (Age 50)
Chief Technology Officer
Comp: $380k
Dr. Robert B. Den M.D. (Age 44)
Chief Medical Officer & Member of Scientific Advisory Board
Comp: $565k
Prof. Yona Keisari (Age 76)
Chief Scientific Officer & Member of Scientific Advisory board
Ms. Rebecca Becker
Vice President of legal
Mr. Peter M. Melnyk (Age 61)
Chief Commercial Officer
Prof. Itzhak Kelson (Age 83)
Chief Physics Officer & Member of Scientific Advisory Board
Ms. Yael Zeiger (Age 40)
Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpha Tau Medical stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRTS shares.
View DRTS analyst ratings or view top-rated stocks.
What is Alpha Tau Medical's stock price target for 2024?: 3 equities research analysts have issued 1 year price targets for Alpha Tau Medical's shares. Their DRTS share price targets range from $8.00 to $23.00. On average, they anticipate the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts.
How have DRTS shares performed in 2023?: Alpha Tau Medical's stock was trading at $3.18 on January 1st, 2023. Since then, DRTS shares have increased by 0.6% and is now trading at $3.20.
View the best growth stocks for 2023 here.
Are investors shorting Alpha Tau Medical?: Alpha Tau Medical saw a decrease in short interest in November. As of November 15th, there was short interest totaling 65,100 shares, a decrease of 8.2% from the October 31st total of 70,900 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is presently 2.5 days. Currently, 0.2% of the shares of the company are short sold.
View Alpha Tau Medical's Short Interest.

When is Alpha Tau Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our DRTS earnings forecast.
How were Alpha Tau Medical's earnings last quarter?: Alpha Tau Medical Ltd. (NASDAQ:DRTS) issued its quarterly earnings results on Thursday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05.
Who are Alpha Tau Medical's major shareholders?: Alpha Tau Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hoylecohen LLC (0.39%), Levin Capital Strategies L.P. (0.12%) and Citigroup Inc. (0.02%).
How do I buy shares of Alpha Tau Medical?: Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DRTS) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial